­
­
­
­

Inventi Impact: Oncology

Articles

  • Inventi:hoc/25106/18
    Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction\nas Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
    01-Jan-1970 Research 2018 : April - June
    Prihantono Prihantono, Mochammad Hatta, Christian Binekada, Daniel Sampepajung, Haryasena Haryasena, Berti Nelwan, Andi Asadul Islam, Andi Nilawati Usman

    Background. Chemotherapy has become a standard of treatment in managing breast cancer. To achieve proper treatment for\nthe right patients, the predictive marker is needed. Ki-67 is a biomarker of proliferation for solid tumor. Studies mentioned\nassociation of Ki-67 expression with chemotherapy response. The study aims are to evaluate whether Ki-67 expression detected\nby immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (qRT-PCR) may predict clinical response\nto neoadjuvant chemotherapy in breast cancer. Methods.This study utilized a longitudinal study. IHCand qRT-PCR methods were\nused for detection of Ki-67 expression. Chemotherapy response was calculated using RECIST. Data were analyzed with Chi-square\nand Wilcoxon�s test. Results. There were 48 subjects in this study. Analysis of Ki-67 expression with chemotherapy response has\na significant correlation with

    How to Cite this Article
    CC Compliant Citation: Prihantono Prihantono, Mochammad\nHatta, Christian Binekada, et al., â??Ki-67 Expression by\nImmunohistochemistry and Quantitative Real-Time Polymerase\nChain Reaction as Predictor of Clinical Response to Neoadjuvant\nChemotherapy in Locally Advanced Breast Cancer,â? Journal of\nOncology, vol. 2017, Article ID 6209849, 8 pages, 2017.\ndoi:10.1155/2017/6209849, https://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text